MP
MYGN icon

Manifold Partners’s Myriad Genetics MYGN Stock Holding History

Manifold Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-600
Closed -$14K – 135
2013
Q3 		$14K Buy
+600
New +$17K 0.01% 104

Other funds holding MYGN

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
LCG
Luxor Capital Group New York $2.52B AUM 29.31% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Manifold Partners's MYGN Position: Q4 2013 in Review

Manifold Partners sold out of Myriad Genetics (MYGN) in Q4 2013, closing a stake of 600 shares — an estimated $14K sold.

Manifold Partners first reported a position in MYGN in Q3 2013 and held it in 1 quarter. The position peaked at $14K in Q3 2013. 271 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

  • Manifold Partners reported no remaining Myriad Genetics position as of Q4 2013 after selling out during the quarter.
  • Manifold Partners sold 600 Myriad Genetics shares in Q4 2013, an estimated $14K.
  • Manifold Partners first reported a position in Myriad Genetics in Q3 2013 and held it in 1 quarter.
  • Manifold Partners's Myriad Genetics position peaked at $14K in Q3 2013.
  • 271 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Manifold Partners's 13F filing for Q4 2013, filed 27 Jan 2014.